BACKGROUND: Studies have reported an increased risk for asthma following lower respiratory tract infections, but few studies have specifically assessed this risk in children diagnosed with pneumonia in infancy. Furthermore, it is not fully understood whether this association is indicative of a causal relationship or if certain children have a predisposition for both diseases.

RESEARCH QUESTION: Are children diagnosed with pneumonia in infancy at increased risk for asthma, and what is the role of familial confounding and pneumococcal conjugate vaccine immunization on the association?

STUDY DESIGN AND METHODS: This study was a nationwide register-based cohort analysis of >900,000 Swedish children to assess the association between pneumonia in infancy and prevalent asthma at 4 years. A secondary aim was to assess if the association has changed after the introduction of nationwide pneumococcal conjugate vaccine (PCV) immunization as this has led to a shift in pneumonia etiology. The study controlled for important confounders, including shared environmental and familial confounding, by using sibling analyses.

RESULTS: There was a strong association between pneumonia diagnosis in infancy and prevalent asthma at 4 years (adjusted OR, 3.38; 95% CI, 3.26-3.51), as well as in the full sibling analyses (adjusted OR, 2.81; 95% CI, 2.58-3.06). The risk for asthma following pneumonia diagnosis in infancy was slightly higher for those born in the PCV period compared with the pre-PCV period (adjusted OR, 3.80 [95% CI, 3.41-4.24] vs 3.28 [95% CI, 3.15-3.42]) when the proportion of viral pneumonia etiology was also higher (14.5% vs 10.7%, respectively) and the overall asthma prevalence was lower (5.3% vs 6.6%).

INTERPRETATION: Children diagnosed with pneumonia in infancy have a highly increased risk for prevalent asthma at 4 years, which might have implications for future asthma preventive measures and needs to be considered when assessing the morbidity that can be attributed to pneumonia.

KEY WORDS: asthma; children; epidemiology; family design; pneumonia

ABBREVIATIONS: HR = hazard ratio; ICD-10 = International Classification of Diseases, Tenth Revision; MBR = Medical Birth Register; NPR = National Patient Register; PCV = pneumococcal conjugate vaccine; RSV = respiratory syncytial virus; SPDR = Swedish Prescribed Drug Register; TPR = Total Population Register

AFFILIATIONS: From the Department of Medical Epidemiology and Biostatistics (S. Rhedin, C. Lundholm, E. Caffrey Osvald, and C. Almqvist), Karolinska Institutet, Stockholm, Sweden; Sachs’ Children and Youth Hospital (S. Rhedin), Stockholm, Sweden; and the Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children’s Hospital (E. Caffrey Osvald and C. Almqvist), Karolinska University Hospital, Stockholm, Sweden.

A pilot analysis including parts of the study results was presented as an e-poster at the European Respiratory Society Web-based Congress, September 7-9, 2020.

FUNDING/SUPPORT: This work was supported by the Swedish Research Council [Grant 2018-02640], the Swedish Initiative for Research on Microdata in the Social and Medical Sciences (SIMSAM) framework [Grant 340-2013-5867], the Swedish Research Council for Health, Working Life and Welfare, FORTE [Grant 2015-00289], the Swedish Heart-Lung Foundation [Grant 20180512], the Strategic Research Program in Epidemiology at Karolinska Institutet, the Samariten Foundation for Paediatric Research, and the Sällskapet Barnavård Foundation. S. R. was supported by Region Stockholm (clinical postdoctoral appointment).

CORRESPONDENCE TO: Samuel Rhedin, PhD; email: samuel.rhedin@ki.se

Copyright © 2021 The Authors. Published by Elsevier Inc under license from the American College of Chest Physicians. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

DOI: https://doi.org/10.1016/j.chest.2021.03.006
Asthma is a disease characterized by chronic pulmonary inflammation and bronchial hyperreactivity that contributes to significant morbidity. The etiology of the disease is multifactorial and several risk factors, both genetic and environmental, have been identified. Several studies have reported an association between lower respiratory tract infections and subsequent asthma, but it is not fully understood whether this association is indicative of a causal relationship or if certain children have a predisposition for both diseases. Moreover, children with respiratory syncytial virus (RSV) bronchiolitis have been thoroughly studied, whereas few studies have focused on the risk for subsequent asthma in children with pneumonia. Pneumonia is a lower respiratory tract infection affecting the lung parenchyma, predominantly caused by the bacteria Streptococcus pneumoniae that contributes to significant morbidity. Historical birth cohort studies have reported an increased risk for impaired lung function in children diagnosed with pneumonia in childhood. However, the generalizability of these studies can be questioned given the changes in socioeconomic status, control of tobacco use, and childhood immunization that have occurred over the last decades. Furthermore, by using family design (a quasi-experimental design in which genetically related study subjects [such as siblings and half-siblings] with different exposure are compared regarding the outcome), it is possible to control for unmeasured familial confounding (ie, environmental and genetic confounding shared by the siblings or half-siblings).

Introduction of pneumococcal conjugate vaccine (PCV) immunization has coincided with an overall reduction in pneumonia hospitalization rates among children and also resulted in a relative increase of viral etiology of the disease. In Sweden, nationwide immunization with PCV was implemented during 2007 to 2009, reaching a high coverage (> 96%) from 2011. In previous studies, viral pneumonia has been associated with the highest risk for asthma. Hence we hypothesized that the risk for asthma following a pneumonia diagnosis would be higher after the introduction of nationwide PCV immunization.

The primary aim of the current study was to assess the association between pneumonia diagnosis in infancy and prevalent asthma at 4 years, while controlling for important confounders, including shared genetic and familial confounding. The secondary aim was to assess if the association between pneumonia diagnosis in infancy and asthma at 4 years has changed following the introduction of nationwide PCV immunization.
physician’s diagnosis in the NPR and dispensed asthma medications in the SPDR (e-Appendix 1).22,23 A secondary outcome was incident asthma/wheezing defined as fulfilling the definition for prevalent asthma at any time point during the study period.

Pneumonia in infancy was defined as a record of pneumonia (J10.0, J11.0, or J12-J18) prior to 2 years of age in the NPR. Repeated records within a time period of 8 weeks were considered to represent the same pneumonia episode, which takes into account potential routine check-ups, according to clinical practice in Sweden. Children who experienced > 2 pneumonia episodes prior to 2 years of age were excluded as these could have other underlying conditions potentially associated with asthma.21

Potential confounders were assessed based on qualitative assessment of the previous literature on associations between covariates and the exposure/outcome using directed acyclic graphs (e-Fig 1).27 Data on sex, prematurity (gestational age < 37 weeks), cesarean section, small for gestational age (< 2 SDs below expected length or weight), pregnancy type (single/multiple birth), maternal smoking during pregnancy, and parity were collected from the MBR. Data on comorbidities were collected from the NPR (e-Table 1). Data on educational level and parents’ birth country were collected from the Longitudinal Integration Database for Labour Market Studies and the TPR. Parental asthma was defined according to physician’s diagnosis and dispensed asthma medications.22
To assess potential effect modification from PCV immunization, the pneumonia episodes were classified as occurring in the pre-PCV period or the PCV period separated by a washout period of 3 months prior to and 9 months following the immunization starting date in each county (Fig 1B). Data on birth county were collected from the MBR.

To assess the potential impact of pneumonia etiology, the exposure was classified as bacterial/unspecified (J13-J18) or viral (J10.0, J11.0, and J12) according to ICD-10 codes. Because most viruses associated with pneumonia are almost nonexistent during summer and fall, we further classified the exposure as occurring during or outside the respiratory infections season.17

Statistical Analyses

Logistic regression was used to assess the association between pneumonia in infancy and prevalent asthma, and data are presented as ORs and 95% CIs. For the adjusted estimates, two models were constructed: the first model included individual confounders (sex, prematurity, cesarean section, small for gestational age, and parity), whereas the second model also included parental factors (maternal smoking during pregnancy, educational level of parents, parents’ birth country, and parental asthma).

Etiologic fraction for asthma and 95% CIs were calculated as pneumonia prevalence in children with prevalent asthma × (adjusted OR – 1)/ adjusted OR × 100.26

To explore confounding from familial factors, full siblings and half-siblings were identified by using the Multi-Generation Register, and all possible sibling pairs were created.Sibling comparisons were performed following exclusion of twins and multiple births using conditional logistic regression for each type of relatedness (ie, full siblings, maternal and paternal half-siblings) separately, conditioning on sibling pair, and using cluster robust SEs to account for dependence due to multiple sibling pairs within families. In the sibling analyses, adjustments were only made for individual confounders because parental factors are shared between siblings and adjusted for by design.

To assess the association between pneumonia diagnosis in infancy and incident asthma/wheezing, hazard ratios (HRs) and 95% CIs were estimated by using Cox regression analysis with pneumonia as a time-varying exposure considering pneumonia diagnoses either the first 2 years of life or any time during the study period. These analyses were performed in the survival analysis cohort also including children who emigrated or were deceased prior to 5 years but censored at death or emigration. However, 65 children were excluded due to dates for prescription of asthma medication or emigration being falsely coded as occurring before date of birth (Fig 2). Date of asthma onset was defined as the first record of either asthma medication or asthma diagnosis. Adjusted analyses (using confounders as noted earlier) were performed.

The proportional hazards assumption was tested by using Schoenfeld residuals, which indicated nonproportionality (P < .001). Hence, we allowed for time-varying effects, assuming piecewise constant hazards 0 to 2 years and > 2 years based on graphical examination of the log hazards curves.

Five sensitivity analyses were performed (e-Appendix 1). All data analyses were conducted by using Stata version 16 (StataCorp). The Regional Ethical Review Board in Stockholm granted permission for the study.
Results

Description of Study Cohort
A total of 948,045 children were included in the study; of these, 23,086 (2.4%) children were diagnosed with pneumonia prior to 2 years of age. Male sex, prematurity, cesarean section, small for gestational age, maternal smoking during pregnancy, comorbidities, low parental educational level, and parental asthma were all overrepresented in children diagnosed with pneumonia compared with unexposed children (Table 1).

Asthma Following Pneumonia Exposure
A total of 60,565 (6.4%) children had prevalent asthma at 4 years, and the cumulative incidence of asthma was 11.6% during the study period. Children diagnosed with pneumonia were more likely to have prevalent asthma at 4 years compared with unexposed children (18.9% vs 6.1%; crude OR, 3.59; 95% CI, 3.47-3.71) (e-Table 2, Fig 3). The point estimates were slightly attenuated in the adjusted models (adjusted OR, 3.38; 95% CI, 3.26-3.51). The etiologic fraction of asthma due to pneumonia diagnosis in infancy was 5.1% (95% CI, 4.7-5.4).

To adjust for genetic and shared familial confounding, sibling and half-sibling analyses were performed. After exclusion of twins, a total of 329,285 full sibling pairs, 17,312 maternal half-sibling pairs, and 16,558 paternal half-sibling pairs remained. The OR for prevalent asthma at 4 years following pneumonia diagnosis in infancy was 2.88 (95% CI, 2.65-3.14) in the full sibling analysis and 1.92 (95% CI, 1.37-2.68) and 2.28 (95% CI, 1.63-3.18) when assessing maternal and paternal half-sibling pairs, respectively (e-Table 2, Fig 3).

| TABLE 1 | Sociodemographic Characteristics of Study Subjects |
|---------|---------------------------------------------------|
| Characteristic | All (N = 948,045) | Pneumonia Diagnosis < 2 y | Pneumonia Diagnosis < 2 y |
| Male sex | 487,513 (51.3) | 474,379 (51.3) | 13,134 (56.9) |
| Prematurity (< 37 wk) | 57,128 (6.0) | 54,620 (5.9) | 2,508 (10.9) |
| Cesarean section | 165,839 (17.5) | 160,906 (17.4) | 4,933 (21.4) |
| Small for gestational age | 20,215 (2.2) | 19,441 (2.2) | 774 (3.5) |
| Multiple birth | 27,341 (2.9) | 26,379 (2.9) | 962 (4.2) |
| Maternal smoking during pregnancy | 72,863 (7.8) | 70,863 (8.1) | 2,000 (9.2) |
| Comorbidity (any) | 50,482 (5.3) | 47,649 (5.2) | 2,833 (12.3) |
| Respiratory malformations | 2,486 (0.3) | 2,066 (0.2) | 420 (1.8) |
| Cardiac malformations | 18,698 (2.0) | 17,471 (1.9) | 1,227 (5.3) |
| Cerebral palsy/paralytic syndromes | 2,424 (0.3) | 2,182 (0.2) | 242 (1.1) |
| Neonatal respiratory/cardiac disorders | 30,139 (3.2) | 28,611 (3.1) | 1,528 (6.6) |

| Highest parental education | | | |
| Primary school (9 y) | 53,307 (5.6) | 51,716 (5.6) | 1,591 (6.9) |
| Secondary school (12 y) | 356,941 (37.7) | 348,092 (37.7) | 8,849 (38.4) |
| University studies (> 12 y) | 492,071 (52.0) | 488,588 (52.0) | 11,483 (49.8) |

| Birth country of parents | | | |
| Mother born in Sweden | 764,231 (80.6) | 746,117 (80.7) | 18,114 (78.5) |
| Mother born in other Nordic country | 14,506 (1.5) | 14,128 (1.5) | 378 (1.6) |
| Father born in Sweden | 755,763 (80.4) | 737,994 (80.5) | 17,769 (77.6) |
| Father born in other Nordic country | 15,081 (1.6) | 14,685 (1.6) | 396 (1.7) |

| Parity, mean ± SD | | | |
| Maternal asthma | 132,047 (13.9) | 128,036 (13.8) | 4,011 (17.4) |
| Paternal asthma | 104,939 (11.1) | 102,000 (11.0) | 2,939 (12.7) |

Data are expressed as absolute number and percentage if not otherwise specified.
were only slight changes in the point estimates when additional controlling for individual confounders was performed (adjusted OR, 2.81; 95% CI, 2.58-3.06 in the full sibling analysis).

To assess incident asthma/wheezing over time, a Cox regression analysis was performed (Table 2). The HR for asthma/wheezing was higher during the first 2 years of life compared with following 2 years of age (adjusted HRs of 4.31 [95% CI, 4.11-4.51] and 1.67 [95% CI, 1.59-1.76], respectively).

Effect Modification From PCV

A total of 709,649 children were born in the pre-PCV period and 132,112 in the PCV period. Of these, 46,499 (6.6%) of the children born in the pre-PCV period and 6,988 (5.3%) born in the PCV period fulfilled the criteria for prevalent asthma at 4 years (P < .001). There was significant effect modification from PCV immunization, with slightly higher OR for asthma in the PCV period compared with the pre-PCV period (adjusted ORs of 3.80 [95% CI, 3.41-4.24] vs 3.28 [95% CI, 3.15-3.42]) (Table 3).

The majority (88.7%) of pneumonia episodes were classified as bacterial/unspecified and 11.3% as viral. The proportion of viral etiology was significantly higher in the PCV period compared with the pre-PCV period (14.5% vs 10.7%, respectively; P < .001). There were minor differences in ORs for asthma comparing children diagnosed with pneumonia during or outside the respiratory infections season (Table 3).

Sensitivity Analyses

The first four sensitivity analyses did not result in any major changes of the point estimates (e-Table 3). In the fifth sensitivity analysis, the association of pneumonia diagnosis in infancy and the risk for asthma was assessed following exclusion of all children with a record of any dispensed asthma medication or asthma diagnosis before 2 years of age. This resulted in a markedly decreased asthma prevalence (3.4%) and clearly attenuated but still significant point estimates (adjusted OR, 1.66; 95% CI, 1.48-1.87).

Discussion

In this large-scale register-based cohort study, we report a strong association between pneumonia diagnosis in infancy and prevalent asthma at 4 years of age and that the strength of the association has increased slightly after the introduction of PCV immunization, possibly related to a relative increase in viral pneumonia etiology. Children diagnosed with pneumonia in infancy had clearly increased odds for asthma even following adjustments for important confounders, including shared genetic and familial environment assessed by using sibling analyses.

| Exposure/Outcome                  | Unadjusted HR (95% CI) | Model 1a Adjusted HR (95% CI) | Model 1b Adjusted HR (95% CI) |
|----------------------------------|-------------------------|--------------------------------|--------------------------------|
| Pneumonia diagnosis < 2 y        |                         |                                |                                |
| Asthma/wheezing 0-2 y            | 4.58 (4.38-4.78)        | 4.37 (4.18-4.57)               | 4.31 (4.11-4.51)               |
| Asthma/wheezing > 2 y            | 1.75 (1.66-1.83)        | 1.68 (1.60-1.76)               | 1.67 (1.59-1.76)               |
| Pneumonia diagnosis ever         |                         |                                |                                |
| Asthma/wheezing 0-2 y            | 4.58 (4.38-4.78)        | 4.37 (4.18-4.57)               | 4.31 (4.11-4.51)               |
| Asthma/wheezing > 2 y            | 2.28 (2.20-2.36)        | 2.19 (2.11-2.27)               | 2.18 (2.10-2.26)               |

HRs for incident asthma following pneumonia exposure calculated by using Cox regression. HR = hazard ratios.

aAdjusted for sex, prematurity, cesarean section, small for gestational age, and parity.

bAdjusted for sex, prematurity, cesarean section, small for gestational age, maternal smoking during pregnancy, parity, educational level of parents, birth country of parents, and parental asthma.
Our findings are in line with a study by Chan et al,\textsuperscript{21} who reported an increased risk for asthma (OR, 1.95; 95% CI, 1.11-3.44) assessed by spirometry at 11 to 26 years of age following pneumonia exposure in infancy in an American birth cohort study of >1,000 children born 1980 to 1984. We expand this further by also adjusting for familial confounding and addressing potential effect modification from PCV immunization. Their lower point estimates could potentially be explained by a longer follow-up period and a more strict definition of asthma based on spirometry at 11 to 22 years of age, as some children outgrow their asthma during adolescence but could also be a result of loss of follow-up or differences in etiology. Other birth cohort studies have reported a strong long-term risk for predominantly restrictive deficits.\textsuperscript{13,14} Several studies have suggested that viral pneumonia is more strongly associated with asthma than bacterial pneumonia.\textsuperscript{8,29} This is further supported by a Dutch randomized controlled study by Blanken et al\textsuperscript{4} showing that RSV prophylaxis with palivizumab is associated with a reduction in recurrent wheezing and parental reported asthma; however, the follow-up study did not reach the primary outcome of a reduction in physician-diagnosed asthma at 6 years of age.\textsuperscript{10} There are limited data on the association between pneumonia and asthma in low-income countries. Data from a South African birth cohort suggest that lower respiratory tract infections in infancy are associated with decreased lung function and recurrent wheeze.\textsuperscript{27,28}

Several different biological mechanisms could explain the association between pneumonia diagnosis and asthma, including direct damage to the lung parenchyma, immunomodulatory mechanisms, or disturbance of lung development during a critical phase. In mouse models, pneumococcal pneumonia has been shown to alter the expression of airway smooth muscle proteins, whereas RSV infection has been associated with immune modulation and airway hyperresponsiveness.\textsuperscript{29,30}

It has been argued that some children are genetically predisposed for both severe respiratory tract infections and asthma, and it has not been clear whether there is a causal association between the respiratory infection and development of asthma.\textsuperscript{31} By using a quasi-experimental design with sibling controls, we were able to further expand the previous knowledge on the association between pneumonia and asthma.\textsuperscript{16} Briefly, the rational for the sibling analyses is to control for unmeasured familial confounding (ie, environmental or genetic factors shared by the siblings or half-siblings). If the point estimates in the sibling analysis are attenuated compared with those in the standard observational analyses, it suggests that the association is confounded by familial factors. In contrast, if the effect remains in the sibling analyses, it does not prove, but provides additional support for, a causal link between the studied exposure and the outcome, as compared with ordinary analyses of observational studies.\textsuperscript{16} In our study, the

\textbf{TABLE 3}  
\textbf{Association Between Pneumonia Diagnosis in Infancy and Prevalent Asthma in Relation to PCV Immunization and Season of Exposure}

| Variable                                      | Unadjusted OR (95% CI) | Model 1\textsuperscript{a} Adjusted OR (95% CI) | Model 2\textsuperscript{b} Adjusted OR (95% CI) | P Value for Interaction\textsuperscript{c} |
|-----------------------------------------------|------------------------|--------------------------------------------------|--------------------------------------------------|------------------------------------------|
| PCV immunization period                       |                        |                                                  |                                                  |                                          |
| Pre-PCV                                       | 3.50 (3.37-3.63)       | 3.33 (3.20-3.47)                                | 3.28 (3.15-3.42)                                | .015                                     |
| PCV                                           | 4.06 (3.67-4.50)       | 3.92 (3.53-4.35)                                | 3.80 (3.41-4.24)                                |                                          |
| Season of pneumonia diagnosis                 |                        |                                                  |                                                  |                                          |
| Respiratory infections season (December-April) | 3.49 (3.36-3.64)       | 3.35 (3.22-3.49)                                | 3.28 (3.14-3.42)                                | .015                                     |
| Outside respiratory infections season (May-November) | 3.88 (3.63-4.13)   | 3.65 (3.41-3.90)                                | 3.63 (3.38-3.89)                                |                                          |

\textsuperscript{a}Adjusted for sex, prematurity, cesarean section, small for gestational age, and parity.

\textsuperscript{b}Adjusted for sex, prematurity, cesarean section, small for gestational age, parity, maternal smoking during pregnancy, educational level of parents, birth country of parents, and parental asthma.

\textsuperscript{c}Indicates \textit{P} for interaction of model 2.
We assessed effect modification from PCV immunization, as nationwide PCV immunization of children was introduced during the study period, which has likely changed the etiology of pediatric pneumonia. Children born in the PCV period had a slightly increased risk for asthma if diagnosed with pneumonia in infancy compared with those born in the pre-PCV period. This supports the hypothesis that viral pneumonia is more strongly associated with asthma and that the absolute risk for asthma in children experiencing pneumonia in infancy is somewhat higher today, potentially owing to the relative increase in viral etiology of childhood pneumonia. Further supporting this hypothesis was an observed relative increase in viral pneumonia diagnosis codes in the PCV period compared with the pre-PCV period and higher point estimates when restricting the exposure definition to only include viral pneumonia diagnosis codes in a sensitivity analysis. However, specific ICD-10 codes should be interpreted cautiously as pneumonia etiology is hard to establish in children, and coding practices might change over time. As an alternative approach, we compared children diagnosed with pneumonia during and outside the respiratory infections season but observed only minor differences in the point estimates. Of note, we observed an overall lower asthma prevalence in children born in the PCV period compared with those born in the pre-PCV period. This raises questions about a potential asthma-reducing effect of PCV, although this topic is beyond the scope of the current study.

Because asthma itself is a risk factor for severe pneumonia, there is a risk of potential reverse causation (ie, the asthma disease was already present at the time for exposure and thus increased the risk for acquiring pneumonia). However, in a survival analysis where we allowed for both time-varying exposure and time-varying effect, there was still a clear association between pneumonia and incident asthma/wheezing. Nevertheless, the association was weaker following 2 years of age compared with during the first 2 years. This finding is likely partly explained by the fact that the majority of wheezing episodes prior to 2 years of age represents viral-induced wheeze rather than true asthma. We also performed a sensitivity analysis, in which all children with an asthma diagnosis or any dispensed asthma medication prior to 2 years of age were excluded to ascertain that the pneumonia preceded the asthma diagnosis. In this analysis, the point estimates were clearly attenuated, but the association was still present. Together, this points toward an immediate increased risk for asthma following pneumonia exposure in the youngest children, coinciding with a critical phase of the lung development and maturation of the immune system and potentially representing an infectious asthma phenotype that, to a higher degree, can be outgrown. We cannot, however, completely rule out reverse causation (ie, the increased risk for asthma seen in children diagnosed with pneumonia in infancy was partly explained by undiagnosed asthma at the time of exposure). There are also studies suggesting that respiratory infections might trigger asthma development in the presence of certain genetic variants, further complicating the interpretation of the direction of the association.

A strength of the study was the large study population covering the entire Swedish population including >900,000 children, the nearly complete follow-up data owing to high-quality health and population registers held in Sweden, previously validated definitions of asthma, and our family-based approach specifically assessing environmental and genetic confounding shared between siblings. This allowed proper controlling for several important confounders, as well as assessment of effect modification from PCV immunization.

There are also some limitations of the study. First, pneumonia in children is mainly diagnosed clinically, and the disease presentation of pneumonia, other lower respiratory tract infections, and asthma overlaps. To account for this, some epidemiologic pneumonia studies have used a radiology-based case definition favoring specificity over sensitivity, whereas we assessed physician-diagnosed pneumonia according to ICD-10 codes. According to clinical practise in Sweden, a large proportion (although not all) of infants with pneumonia have a radiology-based diagnosis. Using a strict radiographic pneumonia definition provides a more robust but less sensitive definition, which affects the generalizability as a large number of children are clinically diagnosed with pneumonia. It is possible, however, that in our study, some wheezing episodes early in life were misclassified as pneumonia, potentially overestimating the association. Second, we could not include visits to general practitioners, as they are not recorded in the NPR. However, there are national guidelines from the Swedish Public Health Agency and
the Medical Products Agency recommending that children with suspected pneumonia should be referred to a pediatric clinic if they are < 6 months of age or if they present with respiratory distress (age-adjusted tachypnea, grunting, severe indrawings, or peripheral oxygen saturation < 93%). 39 Hence, the vast majority of pneumonia episodes should be included. Third, the diagnosis of asthma in young children is complex and represents a heterogenous group of wheezing phenotypes. 34,40 We assessed prevalent asthma at 4 years of age as our main outcome, using a previously validated algorithm based on both physician’s diagnosis and dispensed asthma medication requiring evidence of an active disease during the fourth year of life and also performed several different sensitivity analyses that did not have any major effects on the point estimates. 22

Future studies should assess the long-term risk for asthma following pneumonia diagnosis, target beneficial effects from pneumonia interventions (including PCV immunization), and explore the association between pneumonia and asthma in low-income countries, where currently limited data are available but where future interventions would likely have the most impact.

Interpretation

We report that pneumonia diagnosis in infancy is strongly associated with prevalent asthma at 4 years despite controlling for important confounders, including genetic and shared familial environment. If this association is causal, it implies further beneficial effects from interventions targeting pneumonia.

Acknowledgments

Author contributions: S. R. is the guarantor of the content of the manuscript, including the data and analysis. S. R. conceptualized the study, had a leading role in the study design, performed the statistical analyses, and wrote the first draft of the manuscript; E. C. O. contributed substantially to the study design, data analysis, and interpretation, as well as to the writing of the manuscript; C. L. took part in the study design, provided support regarding statistical analyses and data management, and contributed to the data analysis, interpretation, and the writing of the manuscript; and C. A. had a leading role in the study design and collection of the data and contributed to the data analysis, interpretation, and the writing of the manuscript. All authors critically revised and approved the final version of the manuscript.

Financial/nonfinancial disclosures: None declared.

Additional information: The e-Appendix, e-Figure, and e-Tables can be found in the Supplemental Materials section of the online article.

References

1. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743.
2. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783-800.
3. Ferreira MAR, Mathur R, Vonk JM, et al. Genetic architectures of childhood- and adult-onset asthma are partly distinct. Am J Hum Genet. 2019;104(4):665-684.
4. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791-1799.
5. Thomsen SF, van der Sluis S, Stensballe LG, et al. Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study. Am J Respir Crit Care Med. 2009;179(12):1091-1097.
6. Almqvist C, Ekberg S, Rhedin S, Fang F, Fall T, Lundholm C. Season of birth, childhood asthma and allergy in a nationwide cohort-mediation through lower respiratory infections. Clin Exp Allergy. 2020;50(2):222-230.
7. Drysdale SB, Wilson T, Alcazar M, et al. Lung function prior to viral lower respiratory tract infections in prematurely born infants. Thorax. 2011;66(6):468-473.
8. Edmond K, Scott S, Korczak V, et al. Long-term sequelae from childhood pneumonia: systematic review and meta-analysis. PLoS One. 2012;7(2):e31239.
9. Marlow R, Finn A, Henderson J. Assessing the association between bronchiolitis in infancy and recurrent wheeze: a whole English birth cohort case-control study. Thorax. 2019;74(5):503-505.
10. Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respir Med. 2018;6(4):257-264.
11. Troeger C, Blacker B, Khalil I, et al. Estimates of the global, regional, and national morbidity, mortality, and aetologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-1210.
12. Burgess JA, Abramson MJ, Gurrin LC, et al. Childhood infections and the risk of asthma: a longitudinal study over 37 years. Chest. 2012;142(3):647-654.
13. Johnston ID, Strachan DP, Anderson HR. Effect of pneumonia and whooping cough in childhood on adult lung function. N Engl J Med. 1998b;338(9):581-587.
14. Perret JL, Lodge CJ, Lowe AJ, et al. Childhood pneumonia, pleurisy and lung function: a cohort study from the first to sixth decade of life. Thorax. 2020;75(1):28-37.
15. Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2071-2094.
16. Gong T, Brew B, Sjölander A, Almqvist C. Towards non-conventional methods of designing register-based epidemiological studies: an application to pediatric research. Scand J Public Health. 2017;45(suppl 17):30-35.
17. Rhedin S, Lindstrand R, Hjelmgren A, et al. Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study. Thorax. 2015;70(9):847-853.
18. Lindstrand A, Bennett R, Galanis I, et al. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. Pediatrics. 2014;134(6):e1528-e1536.
19. Shiri T, McCarthy ND, Petrou S. The impact of childhood pneumococcal vaccination on hospital admissions in England: a whole population observational study. BMC Infect Dis. 2019;19(1):510.
20. Sweden TPHAo. Folkhälsodata [Swedish]. http://fohm-app.folkhalsomyndigheten.se/Folkhalsodata/pxweb/sv/A_Folkhalsodata/A_Folkhalsodata_1_Tidigalivetsvillkor_eBarnvaccin/Barnvacc.px/table/tableViewLayout1?rxid¼12c90dbb-bf56-a452-b422-353b07da3c82. Accessed April 26, 2021.
21. Chan JY, Stern DA, Guerra S, Wright AL, Morgan WJ, Martinez FD. Pneumonia in childhood and impaired lung function in adults: a longitudinal study. *Pediatrics*. 2015;135(4):607-616.

22. Ortqvist AK, Lundholm C, Wettermark B, Ludvigsson JF, Ye W, Almqvist C. Validation of asthma and eczema in population-based Swedish drug and patient registers. *Pharmacoepidemiol Drug Saf*. 2013;22(8):850-860.

23. Hedman AM, Gong T, Lundholm C, et al. Agreement between asthma questionnaire and health care register data. *Pharmacoepidemiol Drug Saf*. 2018;27(10):1139-1146.

24. Panitch HB. Evaluation of recurrent pneumonia. *Pediatr Infect Dis J*. 2005;24(3):265-266.

25. Textor J, van der Zander B, Gilthorpe MS, Liskiewicz M, Ellison GT. Robust causal inference using directed acyclic graphs: the R package ‘dagitty’. *Int J Epidemiol*. 2016;45(6):1887-1894.

26. Rothman K, Greenland S. Applications of stratified analysis methods. In: *Modern Epidemiology*, Vol. 41. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:295-297.

27. Gray DM, Turkovic L, Willems L, et al. Lung function in African infants in the Drakenstein Child Health Study. Impact of lower respiratory tract illness. *Am J Respir Crit Care Med*. 2017;195(2):212-220.

28. Zar HJ, Nduru P, Stadler JAM, et al. Early-life respiratory syncytial virus lower respiratory tract infection in a South African birth cohort: epidemiology and effect on lung health. *Lancet Glob Health*. 2020;8(10):e1316-e1325.

29. Peng X, Wu Y, Kong X, et al. Neonatal *Streptococcus pneumoniae* pneumonia induces an aberrant airway smooth muscle phenotype and AHR in mice model. *Biomed Res Int*. 2019;2019:1948519.

30. Schwarze J, Hamelmann E, Bradley KL, Takeda K, Gelfand EW. Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. *J Clin Invest*. 1997;100(1):226-233.

31. Driscoll AJ, Arshad SH, Bont L, et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. *Vaccine*. 2020;38(11):2435-2448.

32. Eriksson M, Nilsson A, Bennet R. Changing diagnosis coding routines may confound the results of longitudinal childhood pneumonia studies. *Acta Paediatr*. 2017;106(11):1825-1829.

33. Rhedin S. Establishment of childhood pneumonia cause in the era of pneumococcal conjugate vaccines. *Lancet Respir Med*. 2016;4(6):423-424.

34. Ducharme FM, Tse SM, Chauhan B. Diagnosis, management, and prognosis of preschool wheeze. *Lancet*. 2014;383(9928):1593-1604.

35. Çalışkan M, Bochkov YA, Kreiner-Møller E, et al. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med*. 2013;368(15):1398-1407.

36. Douroš K, Everard ML. Time to say goodbye to bronchiolitis, viral wheeze, reactive airways disease, wheeze bronchitis and all that. *Frontiers Pediatrics*. 2020;8(218).

37. Cherian T, Mulholland EK, Carlin JB, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. *Bull World Health Organ*. 2005;83(5):353-359.

38. Goodman D, Crocker ME, Pervaiz F, et al. Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group. *Lancet Respir Med*. 2019;7(12):1068-1083.

39. Läkemedelsverket. *Farmakologisk behandling av nedre luftvägsinfektioner i öppenvård*. Information från läkemedelsverket; 2008 [Swedish]. https://www.lakemedelsverket.se/481f5/globalassets/dokument/behandling-och-forskriftning/behandlingsrekommandationer/bakgrunds dokumentation-antibiotika-vid-nedre-luftvagsinfektion.pdf. Accessed April 26, 2021.

40. Henderson J, Granell R, Heron J, et al. Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. *Thorax*. 2008;63(11):974-980.